1. Introduction {#sec1}
===============

VSs, also known as acoustic neuromas, are histologically benign tumors originating from the eighth nerve. NF2 is a rare autosomal dominant inherited disorder tumor caused by deletion or loss-of-function mutations in the NF2 gene encoding merlin \[[@B1]\]. The main characteristic of NF2-associated VSs is the bilateral schwannomas of the vestibular nerve, which leads to sensorineural hearing loss, facial paralysis, vestibular dysfunction, brainstem compression, and even death \[[@B2]\]. Despite their benign nature, NF2-associated VSs have poor prognosis prone to recurrence, and there are no curative treatments. At present, the primary treatments are follow-up observation, microsurgery, and radiosurgery which are not always effective and sometimes cause neurological deficits \[[@B3]\]. Patients with hearing loss sometimes accept the otolaryngology surgery and require improving or saving hearing. With the targeted molecular therapies becoming increasingly common, drug therapy has gradually become possible. Therefore, it is urgently required to determine effective drug targets for NF2-associated VSs therapies. The present study aimed to determine disease-related genes, pathways, and potential targeted therapeutic drugs associated with NF2-associated VSs using the bioinformatics method.

2. Materials and Methods {#sec2}
========================

2.1. Microarray Datasets {#sec2.1}
------------------------

The gene expression profile GSE108524 of the NF2-associated VSs and normal nerve groups was obtained from the NCBI GEO database. These microarray data were based on GPL17586 Platform \[HTA-2_0\] Affymetrix Human Transcriptome Array 2.0 \[transcript (gene) version\], including 17 NF2-associated VSs tissues and 4 normal nerves.

2.2. Identification of DEGs {#sec2.2}
---------------------------

GEO2R (<http://www.ncbi.nlm.nih.gov/geo/geo2r/>), a web tool based on the analysis of variance or *t*-test, was used to identify DEGs between NF2-associated VSs tissues and normal nerves. The DEGs were identified as the genes with \|log FC\| ≥ 1.5 and adj. *P* \< 0.05.

2.3. Functional and Pathway Enrichment Analysis of DEGs {#sec2.3}
-------------------------------------------------------

The Database for Annotation, Visualization, and Integrated Discovery (DAVID) (Version 6.8, <https://david.ncifcrf.gov/>) was used to perform GO and KEGG pathway enrichment analysis of DEGs. GO analysis contains biological process (BP), cellular component (CC), and molecular function (MF). GO term with the criterion of *P* \< 0.05 and false discovery rate (FDR) \< 0.05 and KEGG pathway analysis with the criterion of *P* \< 0.05 were considered statistically significant.

2.4. Protein-Protein Interaction (PPI) Network Analysis {#sec2.4}
-------------------------------------------------------

We submitted DEGs in Search Tool for the Retrieval of Interacting Genes database (STRING, <http://www.string-db.org/>) to screen the PPI pairs with a combined score of ≥0.4 and visualized the interaction using Cytoscape software (Version 3.7.0.). Finally, CentiScaPe and Molecular Complex Detection (MCODE), a Cytoscape plugin, were utilized to screen PPI network key genes. The default parameters of MCODE were used: degree cutoff ≥2, node score cutoff ≥0.2, k-score  ≥ 2, and maximum depth = 100.

2.5. Drug-Gene Interaction Analysis {#sec2.5}
-----------------------------------

To better identify potential targeted therapeutic drugs for NF2-associated VSs, the hub genes were mapped onto the Drug-Gene Interaction database (DGIdb; <http://www.dgidb.org>) to obtain potential drug target genes and potential NF2-associated VSs treatment drugs. Visualization of the drug-gene interaction was generated using Cytoscape software (Version 3.7.0.). In addition, [ClinicalTrials.gov](http://ClinicalTrials.gov) ([https://clinicaltrials.gov](https://clinicaltrials.gov/)) was used to identify whether drugs have been previously investigated or are being currently tested in clinical trials.

2.6. Human NF2-Associated VSs Specimens {#sec2.6}
---------------------------------------

Human NF2-associated VSs tissues with the matched normal adjacent specimens were obtained from the Second Hospital of Guangxi Medical University. This study was approved by the Ethics Committee of the Second Hospital of Guangxi Medical University.

2.7. Quantitative PCR (qPCR) {#sec2.7}
----------------------------

Reverse transcription was carried out using SYBR premix EX Taq (Takara, Japan), and SYBR Premix Ex Taq II (Takara) was used for qPCR. We used several sequences: EGFR forward primer 5′-CTACAACCCCACCACGTACC-3′ and reverse primer 5′-CGCACTTCTTACACTTGCGG-3′; GAPDH forward primer 5′-CTTCGCTCTCTGCTCCTCCTGTTCG-3′ and reverse primer 5′-ACCAGGCGCCCAATACGACCAAAT-3. The results were calculated using the 2^−ΔΔCt^ method.

2.8. Statistical Analysis {#sec2.8}
-------------------------

Statistical analysis was conducted by SPSS 20.0 software. The statistical significance between groups was determined using a two-tailed Student\'s *t*-test. Values of *P* \< 0.05 were considered to indicate statistically significant differences.

3. Results {#sec3}
==========

3.1. Identification of DEGs {#sec3.1}
---------------------------

A total of 542 DEGs, including 13 upregulated and 329 downregulated genes, were identified by comparing 17 NF2-associated VSs tissues and 4 normal nerves from GSE108524. The heat map and volcano plot showed these DEGs ([Figure 1](#fig1){ref-type="fig"}).

3.2. Functional Annotation and Pathway Enrichment Analysis of DEGs {#sec3.2}
------------------------------------------------------------------

GO functional annotation revealed that the DEGs were significantly enriched in BP terms including cell adhesion, inflammatory response, immune response, signal transduction, positive regulation of protein kinase B signaling, positive regulation of ERK1 and ERK2 cascade, and positive regulation of GTPase activity. In addition, the CC terms mainly showed plasma membrane, extracellular exosome, extracellular region, extracellular matrix, and membrane raft. MF enrichment indicated heparin binding and integrin binding ([Table 1](#tab1){ref-type="table"}). Furthermore, KEGG pathway enrichment analysis revealed focal adhesion, PI3K-Akt signaling pathway, ECM-receptor interaction, Toll-like receptor signaling pathway, Rap1 signaling pathway, and regulation of actin cytoskeleton ([Table 2](#tab2){ref-type="table"}).

3.3. PPI Network Analysis {#sec3.3}
-------------------------

In total, we made the PPI network of 369 nodes and 1,322 edges, based on the STRING database ([Figure 2(a)](#fig2){ref-type="fig"}). We identified 28 hub genes with connectivity degree ≥20 ([Figure 2(b)](#fig2){ref-type="fig"}, [Table 3](#tab3){ref-type="table"}). Then, using MCODE, three modules with scores \>4.5 and a number of nodes \>18 were selected. Module 1 with a score of 9.368 consisted of 20 nodes and 89 edges ([Figure 2(c)](#fig2){ref-type="fig"}), module 2 with a score of 4.588 comprised 18 nodes and 39 edges ([Figure 2(d)](#fig2){ref-type="fig"}), and module 3 with a score of 4.455 comprised 23 nodes and 49 edges ([Figure 2(e)](#fig2){ref-type="fig"}).

3.4. Drug-Gene Interaction Analysis {#sec3.4}
-----------------------------------

Based on the DGIdb, we use the 28 hub genes to screen for drug-gene interactions, which revealed that 31 drugs associated with 12 key genes may be potential NF2 treatment drugs ([Figure 3](#fig3){ref-type="fig"}). Based on [ClinicalTrials.gov](http://ClinicalTrials.gov), we found that nilotinib was previously investigated for Phase 2 of growing VSs treatment and everolimus is being used in Phase 2 of the NF2 treatment study.

3.5. mRNA Expression Levels of EGFR {#sec3.5}
-----------------------------------

qPCR analysis verified EGFR mRNA underexpression levels in the NF2-associated VSs tissues ([Figure 4](#fig4){ref-type="fig"}).

4. Discussion {#sec4}
=============

In this study, we found that the 28 hub genes had been insufficiently studied or not studied at all in VSs, 12 of which may be target genes for potential NF2 treatment drugs. Among these genes, IL1B, PIK3CG, CSF1R, LYN, FCGR3A, FCGR3B, SPP1, and CCND1 were upregulated in NF2-associated VSs, while EGFR, DCN, VWF, and PDGFRA were downregulated. Then, LYN, FCGR3A, and FCGR3B are involved in "module 1" of the subnetwork, in which GO functional annotation is enriched in inflammatory response and immune response, and KEGG pathway enrichment analysis is enriched in staphylococcus aureus infection, phagosome, and osteoclast differentiation. EGFR and VWF are involved in "module 2," which is enriched in focal adhesion and PI3K-Akt signaling pathway. PIK3CG and SPP1 are involved in "module 3," which is also enriched in focal adhesion and PI3K-Akt signaling pathway.

We found that upregulated genes PIK3CG, CSF1R, SPP1, and CCND1 and downregulated genes EGFR and VWF were significantly enriched in PI3K-Akt signaling pathway involved in VSs development, which can increase schwannoma cell proliferation, survival, and cell-matrix adhesion acting \[[@B4]--[@B6]\]. That may be the cause of poor prognosis in NF2-associated VSs. The drugs that inhibit the PI3K-Akt signaling pathway may be a potential therapeutic strategy for NF2 by antitumor activity against NF2-related tumor cells.

Merlin, a tumor suppressor, is constantly inactivated in NF2-associated VSs. SPP1, also known as osteopontin (OPN), is a secreted, integrin-binding phosphoprotein. OPN had been insufficiently studied in VSs, while elevated OPN is a utility of some tumors progression and metastasis, suggesting a poor prognosis, such as breast cancer \[[@B7]\]. Morrow et al. study \[[@B7]\] revealed that OPN-initiated signaling induced Akt-mediated phosphorylation and degradation of merlin in breast cancer cells; it was reported for the first time that OPN is involved in merlin protein degradation. We showed that SPP1 is upregulated in NF2-associated VSs, consistent with the result of Torres-Martin et al. \[[@B8]\]. SPP1 may be a biomarker of NF2-associated VSs, whose interaction with merlin has not been reported in NF2-associated VSs. Furthermore, we found that drugs associated with SPP1, including tacrolimus and tretinoin, may be potential therapeutic agents for NF2-associated VSs, which require a one-step study. Tacrolimus, a powerful immunosuppressant, significantly increased OPN mRNA and protein expression from kidney tissue and renal cells, which may contribute to nephrotoxicity inducing \[[@B9]\]. However, tacrolimus used to treat autoimmunity blocks IL2 production and is used for active rheumatoid arthritis \[[@B10]\] and lupus nephritis \[[@B11]\]. Based on functional annotation and pathway enrichment analysis of DEGs, inflammatory response, immune response, melanoma, and rheumatoid arthritis may be connected with NF2-associated VSs development. Therefore, tacrolimus may be used for NF2-associated VSs treatment.

In our study, CCND1 involved in apoptosis and cell cycle control, a key cell cycle regulatory protein, was upregulated in NF2-associated VSs, which is consistent with previous studies \[[@B12], [@B13]\]. Elevated CCND1 is known to suggest poor prognosis in many cancers, such as colorectal cancer \[[@B14]\], breast cancer \[[@B15]\], and multiple myeloma \[[@B16], [@B17]\]. We found drugs associated with CCND1, including palbociclib and mycophenolic acid, which had not been studied in VSs. Palbociclib, a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor, prolongs progression-free survival among patients with advanced estrogen receptor-positive and HER2-negative breast cancer \[[@B18], [@B19]\]. Mycophenolic acid, an immunosuppressant, can inhibit proliferation and induce apoptosis in cancer cells, which may be caused by inhibition of upregulation of CCND1 and the PI3K/AKT/mTOR pathway \[[@B20]\]. Very interestingly, CCND1 was also upregulated in NF2-associated VSs and was significantly enriched in the PI3K-Akt signaling pathway in this study. Thus, palbociclib and mycophenolic acid may inhibit the growth of NF2-associated VSs.

In contrast to SPP1 and CCND1, EGFR was downregulated in NF2-associated VSs, in agreement with the results of Torres-Martin et al. \[[@B8]\], but contrary to those of Yi et al. \[[@B21]\]. At present, the efficacy of EGFR inhibitors in acoustic neuroma treatment is not ideal yet, which may be related to EGFR downregulated in some patients.

In conclusion, with the present analysis, we identified 28 drugs not yet tested in NF2-associated VSs. Tacrolimus, palbociclib, and mycophenolic acid may be candidate drugs. SPP1 and CCND1 may be potential targeted genes in NF2-associated VSs. PI3K-Akt signaling pathway may be involved in VSs development.
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![(a) DEGs were selected by volcano plot filtering (\|fold change \| ≥  1.5 and adj. *P* \< 0.05). (b) The heat map of DEGs in NF2-associated VSs (top 100 upregulated and downregulated genes). Green represents a downregulated expression, and red indicates an upregulated level.](JO2020-5976465.001){#fig1}

![(a) The PPI network of DEGs. (b) The hub genes with connectivity degree ≥20. (c) Module 1. (d) Module 2. (e) Module 3. Green represents a downregulated expression, and red indicates an upregulated level.](JO2020-5976465.002){#fig2}

![Drug-gene interactions of hub genes.](JO2020-5976465.003){#fig3}

![The mRNA expression levels of EGFR (^*∗*^*P* \< 0.05).](JO2020-5976465.004){#fig4}

###### 

GO analysis of differentially expressed genes.

  Category   Term                                                             Count   *P* value   FDR
  ---------- ---------------------------------------------------------------- ------- ----------- ---------
  BP         GO:0007155 ∼ cell adhesion                                       38      \<0.001     \<0.001
  BP         GO:0006954 ∼ inflammatory response                               34      \<0.001     \<0.001
  BP         GO:0006955 ∼ immune response                                     32      \<0.001     \<0.001
  BP         GO:0007165 ∼ signal transduction                                 58      \<0.001     0.0054
  BP         GO:0051897 ∼ positive regulation of protein kinase B signaling   12      \<0.001     0.0203
  BP         GO:0070374 ∼ positive regulation of ERK1 and ERK2 cascade        17      \<0.001     0.0261
  BP         GO:0043547 ∼ positive regulation of GTPase activity              34      \<0.001     0.0265
  BP         GO:0030198 ∼ extracellular matrix organization                   18      \<0.001     0.0285
  BP         GO:0030335 ∼ positive regulation of cell migration               17      \<0.001     0.0488
  CC         GO:0005615 ∼ extracellular space                                 87      \<0.001     \<0.001
  CC         GO:0005887 ∼ integral component of plasma membrane               88      \<0.001     \<0.001
  CC         GO:0005886 ∼ plasma membrane                                     177     \<0.001     \<0.001
  CC         GO:0005578 ∼ proteinaceous extracellular matrix                  31      \<0.001     \<0.001
  CC         GO:0009986 ∼ cell surface                                        42      \<0.001     \<0.001
  CC         GO:0070062 ∼ extracellular exosome                               121     \<0.001     \<0.001
  CC         GO:0005576 ∼ extracellular region                                81      \<0.001     \<0.001
  CC         GO:0031012 ∼ extracellular matrix                                28      \<0.001     \<0.001
  CC         GO:0009897 ∼ external side of plasma membrane                    21      \<0.001     \<0.001
  CC         GO:0045121 ∼ membrane raft                                       20      \<0.001     0.0020
  CC         GO:0016021 ∼ integral component of membrane                      179     \<0.001     0.0020
  CC         GO:0005925 ∼ focal adhesion                                      27      \<0.001     0.0122
  CC         GO:0045202 ∼ synapse                                             17      \<0.001     0.0224
  MF         GO:0008201 ∼ heparin binding                                     20      \<0.001     \<0.001
  MF         GO:0005178 ∼ integrin binding                                    14      \<0.001     0.0041

###### 

KEGG pathway analysis of differentially expressed genes.

  Term                                                  Count   *P* value   Genes
  ----------------------------------------------------- ------- ----------- -------------------------------------------------------------------------------------------------------------------------------------------------------------
  hsa05150: staphylococcus aureus infection             13      \<0.001     C3AR1, C3, HLA-DRB3, FPR1, C1R, C1S, HLA-DQA1, FCGR1A, CFH, FCGR3A, CFD, SELPLG, FCGR3B
  hsa04145: phagosome                                   19      \<0.001     MRC1, NOS1, OLR1, C3, TUBB2A, HLA-DRB3, TLR2, HLA-C, C1R, TLR6, HLA-DQA1, CYBB, CD36, FCGR1A, COMP, CLEC7A, FCGR3A, FCGR3B, THBS4
  hsa04514: cell adhesion molecules (CAMs)              16      \<0.001     CLDN19, HLA-DRB3, HLA-C, L1CAM, NLGN3, CDH2, HLA-DQA1, CDH5, ALCAM, NCAM1, CD86, CD34, ITGA8, CLDN1, CD4, SELPLG
  hsa04640: hematopoietic cell lineage                  12      \<0.001     CR1, CD37, CD36, CD34, HLA-DRB3, FCGR1A, MME, IL1B, CD4, ANPEP, CSF2RA, CSF1R
  hsa05144: malaria                                     9       \<0.001     CR1, CD36, COMP, TLR2, IL1B, HBA2, HBA1, HBB, THBS4
  hsa04610: complement and coagulation cascades         10      \<0.001     C3AR1, VWF, CR1, C3, F13A1, CFH, TFPI, C1R, C1S, CFD
  hsa04510: focal adhesion                              17      0.0017      PIK3CG, EGFR, CAV1, TNXB, TNC, FLNB, MYL9, VWF, CCND1, PAK3, CCND2, COMP, ITGA8, COL6A3, PDGFRA, SPP1, THBS4
  hsa04060: cytokine-cytokine receptor interaction      18      0.0022      EGFR, CCL3, TGFBR1, LIFR, EDA2R, CCL4L1, CCL4, CXCL12, IL17RA, LEP, PPBP, CXCL14, CCL3L3, CX3CR1, PDGFRA, IL1B, CSF2RA, CSF1R
  hsa05140: leishmaniasis                               9       0.0027      CR1, C3, HLA-DRB3, FCGR1A, TLR2, IL1B, FCGR3A, FCGR3B, HLA-DQA1
  hsa04151: PI3K-akt signaling pathway                  23      0.0033      EGFR, PIK3CG, FGF7, TNXB, TNC, TLR2, FGF10, IRS1, DDIT4, VWF, CCND1, LPAR5, CCND2, COMP, ITGA8, COL6A3, PDGFRA, MDM2, ANGPT1, FGF1, SPP1, THBS4, CSF1R
  hsa00350: tyrosine metabolism                         6       0.0063      MAOA, AOX1, ADH1C, ADH1B, ADH1A, AOC3
  hsa03320: PPAR signaling pathway                      8       0.0075      LPL, CD36, OLR1, PLIN1, SLC27A6, FABP4, ACADL, ADIPOQ
  hsa04512: ECM-receptor interaction                    9       0.0094      VWF, CD36, TNXB, COMP, TNC, ITGA8, COL6A3, SPP1, THBS4
  hsa04620: Toll-like receptor signaling pathway        10      0.0100      PIK3CG, CD86, CCL3, CCL3L3, TLR2, CCL4L1, IL1B, TLR6, CCL4, SPP1
  hsa05323: rheumatoid arthritis                        9       0.0101      CD86, CCL3, HLA-DRB3, CCL3L3, TLR2, IL1B, ANGPT1, CXCL12, HLA-DQA1
  hsa05218: melanoma                                    8       0.0103      PIK3CG, EGFR, CCND1, FGF7, PDGFRA, MDM2, FGF10, FGF1
  hsa04015: Rap1 signaling pathway                      15      0.0126      FYB, PIK3CG, EGFR, FGF7, FPR1, FGF10, APBB1IP, DOCK4, PLCB4, LPAR5, RASGRP3, PDGFRA, ANGPT1, FGF1, CSF1R
  hsa05416: viral myocarditis                           7       0.0126      CAV1, CD86, CCND1, HLA-DRB3, SGCD, HLA-C, HLA-DQA1
  hsa04730: long-term depression                        7       0.0160      PLA2G4A, PLCB4, NOS1, GRIA2, LYN, GUCY1A2, GUCY1B3
  hsa05206: microRNAs in cancer                         18      0.0176      EGFR, TNXB, CYP1B1, TNC, MIRLET7F1, MIR99A, ZEB1, MIR222, MIR221, IRS1, DDIT4, NOTCH3, CCND1, CCND2, PDGFRA, MDM2, MARCKS, MIR181B2
  hsa05152: tuberculosis                                13      0.0178      MRC1, CR1, ITGAX, C3, FCGR1A, HLA-DRB3, TLR2, IL1B, CLEC7A, FCGR3A, TLR6, FCGR3B, HLA-DQA1
  hsa05205: proteoglycans in cancer                     14      0.0191      PIK3CG, EGFR, CAV1, LUM, FZD1, TLR2, DCN, FLNB, CCND1, CBLB, GPC3, RRAS2, MDM2, PTCH1
  hsa05143: African trypanosomiasis                     5       0.0250      PLCB4, IL1B, HBA2, HBA1, HBB
  hsa05332: graft-versus-host disease                   5       0.0250      CD86, HLA-DRB3, IL1B, HLA-C, HLA-DQA1
  hsa05142: Chagas disease (American trypanosomiasis)   9       0.0254      PIK3CG, CCL3, PLCB4, C3, TGFBR1, CCL3L3, TLR2, IL1B, TLR6
  hsa05200: pathways in cancer                          22      0.0267      EGFR, PIK3CG, FGF7, TGFBR1, FZD1, RUNX1T1, FGF10, CXCL12, CBLB, CCND1, PLCB4, LPAR5, RASGRP3, SLC2A1, PDGFRA, MDM2, PTCH1, PTCH2, HHIP, FGF1, CSF2RA, CSF1R
  hsa04810: regulation of actin cytoskeleton            14      0.0282      PIK3CG, EGFR, FGF7, FGF10, NCKAP1L, MYL9, ARPC1B, ITGAX, CHRM3, PAK3, ITGA8, RRAS2, PDGFRA, FGF1
  hsa04380: osteoclast differentiation                  10      0.0349      PIK3CG, CYBB, FCGR1A, TGFBR1, IL1B, FCGR3A, TREM2, FCGR3B, CSF1R, BLNK

###### 

28 hub genes with connectivity degree ≥20.

  Number   Gene     Degree of connectivity   Regulation
  -------- -------- ------------------------ ------------
  1        EGFR     59                       Down
  2        IL1B     53                       Up
  3        PIK3CG   49                       Up
  4        CSF1R    40                       Up
  5        CXCL12   39                       Down
  6        CD34     36                       Down
  7        EDN1     36                       Down
  8        ITGAX    34                       Up
  9        ACACB    34                       Down
  10       LYN      32                       Up
  11       FCGR3A   32                       Up
  12       DCN      30                       Down
  13       CD36     30                       Down
  14       VWF      30                       Down
  15       CD86     29                       Up
  16       TLR2     29                       Up
  17       ACTA2    29                       Down
  18       LEP      29                       Down
  19       FCGR3B   26                       Up
  20       NCAM1    25                       Up
  21       CAV1     24                       Down
  22       HBA1     23                       Up
  23       ACTG2    22                       Down
  24       SPP1     21                       Up
  25       C3       21                       Up
  26       PDGFRA   20                       Down
  27       CCND1    20                       Up
  28       RRAS2    20                       Up
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